Clinical Experience of Insulin Detemir in Turkey: Efficacy and Safety Data From the PREDICTIVE™ Study

Abstract
Objective: To assess outcomes in Turkish type 1 and 2 diabetic patients given insulin detemir in the multinational PREDICTIVE™ study.
Materials and Methods: PREDICTIVE™ was a large, open-label, prospective, observational study examining the efficacy and safety of insulin detemir in routine clinical practice. Data from the Turkish cohort (2786 patients) were analysed following a 12-week treatment period.
Results: Following treatment, HbA1c significantly decreased by-1.81% (from 9.66%) in type 1 diabetics and by-1.77% (from 9.54%) in type 2 diabetics (P<0.0001). Mean fasting blood glucose (FBG) reduced from 12.35 mmol/L (222.3 mg/dL) to 8.10 mmol/L (145.8 mg/dL) in type 1 diabetics and from 13.46 mmol/L (242.3 mg/dL) to 8.05 mmol/L (144.9 mg/dL) in type 2 diabetics (P<0.0001). Mean within-patient variability of FBG was also reduced (P<0.0001). Serious adverse drug reactions occurred in four patients, 38 if including major hypoglycaemia. Total, major and nocturnal hypoglycaemic events all reduced in frequency after 12 weeks (P<0.0001).
Conclusions: Insulin detemir treatment for 12 weeks resulted in improved, more predictable glycaemic control, modest weight loss or minimal weight gain, and reduced incidence of hypoglycaemia in a large cohort of Turkish patients with diabetes treated according to local clinical practice.